| Assay ID | Title | Year | Journal | Article |
|---|
| AID1541787 | Binding affinity at recombinant human Galectin 2 expressed in Escherichia coli BL21 incubated for 5 mins by fluorescence anisotropy assay | | | |
| AID1766489 | Binding affinity to human galectin-8 N terminal domain assessed as dissociation constant by competitive fluorescence polarization assay | 2021 | ACS medicinal chemistry letters, Nov-11, Volume: 12, Issue:11
| Structure-Guided Design of d-Galactal Derivatives with High Affinity and Selectivity for the Galectin-8 N-Terminal Domain. |
| AID1766486 | Binding affinity to human galectin-4 N terminal domain assessed as dissociation constant by competitive fluorescence polarization assay | 2021 | ACS medicinal chemistry letters, Nov-11, Volume: 12, Issue:11
| Structure-Guided Design of d-Galactal Derivatives with High Affinity and Selectivity for the Galectin-8 N-Terminal Domain. |
| AID1766495 | Selectivity for human galectin-8N over human galectin-1 | 2021 | ACS medicinal chemistry letters, Nov-11, Volume: 12, Issue:11
| Structure-Guided Design of d-Galactal Derivatives with High Affinity and Selectivity for the Galectin-8 N-Terminal Domain. |
| AID1766512 | Selectivity for human galectin-8N over human galectin-8 C terminal domain | 2021 | ACS medicinal chemistry letters, Nov-11, Volume: 12, Issue:11
| Structure-Guided Design of d-Galactal Derivatives with High Affinity and Selectivity for the Galectin-8 N-Terminal Domain. |
| AID1171678 | Antimicrobial activity Pseudomonas aeruginosa PAO1 infected C57BL6/J mouse lung injury model assessed as effect on alveolar-capillary permeability using 1 mM compound pre-treated bacteria for infection | 2014 | Journal of medicinal chemistry, Dec-26, Volume: 57, Issue:24
| Antiadhesive properties of glycoclusters against Pseudomonas aeruginosa lung infection. |
| AID1171656 | Induction of bacterial aggregation in Pseudomonas aeruginosa PAO1 at 6 to 5000 uM by optical microscopy | 2014 | Journal of medicinal chemistry, Dec-26, Volume: 57, Issue:24
| Antiadhesive properties of glycoclusters against Pseudomonas aeruginosa lung infection. |
| AID1171658 | Induction of bacterial aggregation in Pseudomonas aeruginosa PAO1 expressing deltalecB mutant at 6 to 5000 uM by optical microscopy | 2014 | Journal of medicinal chemistry, Dec-26, Volume: 57, Issue:24
| Antiadhesive properties of glycoclusters against Pseudomonas aeruginosa lung infection. |
| AID1541786 | Binding affinity at recombinant human Galectin 1 expressed in Escherichia coli BL21 incubated for 5 mins by fluorescence anisotropy assay | | | |
| AID1171668 | Inhibition of deltalecA mutant expressing Pseudomonas aeruginosa PAO1 adhesion to human A549 cells <250 uM | 2014 | Journal of medicinal chemistry, Dec-26, Volume: 57, Issue:24
| Antiadhesive properties of glycoclusters against Pseudomonas aeruginosa lung infection. |
| AID1541791 | Binding affinity at recombinant human Galectin 7 expressed in Escherichia coli BL21 incubated for 5 mins by fluorescence anisotropy assay | | | |
| AID1171665 | Inhibition of Pseudomonas aeruginosa PAO1 adhesion to human A549 cells 25 to 2500 uM | 2014 | Journal of medicinal chemistry, Dec-26, Volume: 57, Issue:24
| Antiadhesive properties of glycoclusters against Pseudomonas aeruginosa lung infection. |
| AID1181394 | Antagonist activity against human galectin 1 by fluorescence polarization assay | 2014 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
| Synthesis and evaluation of iminocoumaryl and coumaryl derivatized glycosides as galectin antagonists. |
| AID1766514 | Selectivity for human galectin-8N over human galectin-9 C terminal domain | 2021 | ACS medicinal chemistry letters, Nov-11, Volume: 12, Issue:11
| Structure-Guided Design of d-Galactal Derivatives with High Affinity and Selectivity for the Galectin-8 N-Terminal Domain. |
| AID1772857 | Binding affinity to human galactin-3 assessed as dissociation constant by competitive fluorescence polarization assay | 2021 | European journal of medicinal chemistry, Nov-05, Volume: 223 | Benzimidazole-galactosides bind selectively to the Galectin-8 N-Terminal domain: Structure-based design and optimisation. |
| AID1373942 | Substrate activity at Escherichia coli Heptosyltransferase I assessed as ADP release at 100 uM using phospho(enol)pyruvate and NADH by pyruvate kinase and LDH based ADP/NADH coupling assay | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
| Synthesis, kinetics and inhibition of Escherichia coli Heptosyltransferase I by monosaccharide analogues of Lipid A. |
| AID1181397 | Antagonist activity against human galectin 8 N-terminal domain by fluorescence polarization assay | 2014 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
| Synthesis and evaluation of iminocoumaryl and coumaryl derivatized glycosides as galectin antagonists. |
| AID1766490 | Binding affinity to human galectin-8 C terminal domain assessed as dissociation constant by competitive fluorescence polarization assay | 2021 | ACS medicinal chemistry letters, Nov-11, Volume: 12, Issue:11
| Structure-Guided Design of d-Galactal Derivatives with High Affinity and Selectivity for the Galectin-8 N-Terminal Domain. |
| AID343835 | Binding affinity to human galectin4N by fluorescence polarization assay | 2008 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
| Protein subtype-targeting through ligand epimerization: talose-selectivity of galectin-4 and galectin-8. |
| AID513983 | Binding affinity to human galectin 8 N-terminal domain at 20 degC by competitive fluorescence polarization assay | 2010 | Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
| 1H-1,2,3-triazol-1-yl thiodigalactoside derivatives as high affinity galectin-3 inhibitors. |
| AID343838 | Binding affinity to human galectin9N by fluorescence polarization assay | 2008 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
| Protein subtype-targeting through ligand epimerization: talose-selectivity of galectin-4 and galectin-8. |
| AID1181395 | Antagonist activity against human galectin 3 by fluorescence polarization assay | 2014 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
| Synthesis and evaluation of iminocoumaryl and coumaryl derivatized glycosides as galectin antagonists. |
| AID1576032 | Displacement of (3,3'-dideoxy-3-[4-(fluorescein-5-yl-carbonylaminomethyl)-1H-1,2,3-triazol-1-yl]-3'-(3,5-di-methoxybenzamido)-1,1'-sulfanediyl-di-beta-D-galactopyranoside) fluorescent probe from human recombinant galectin-3 expressed in Escherichia coli B | 2019 | MedChemComm, Jun-01, Volume: 10, Issue:6
| Aminopyrimidine-galactose hybrids are highly selective galectin-3 inhibitors. |
| AID1541795 | Binding affinity at recombinant human C-terminal Galectin 9 expressed in Escherichia coli BL21 incubated for 5 mins by fluorescence anisotropy assay | | | |
| AID1766485 | Binding affinity to human galectin-3 assessed as dissociation constant by competitive fluorescence polarization assay | 2021 | ACS medicinal chemistry letters, Nov-11, Volume: 12, Issue:11
| Structure-Guided Design of d-Galactal Derivatives with High Affinity and Selectivity for the Galectin-8 N-Terminal Domain. |
| AID1541788 | Binding affinity at recombinant human Galectin 3 expressed in Escherichia coli BL21 incubated for 5 mins by fluorescence anisotropy assay | | | |
| AID1766491 | Binding affinity to human galectin-9 N terminal domain assessed as dissociation constant by competitive fluorescence polarization assay | 2021 | ACS medicinal chemistry letters, Nov-11, Volume: 12, Issue:11
| Structure-Guided Design of d-Galactal Derivatives with High Affinity and Selectivity for the Galectin-8 N-Terminal Domain. |
| AID1181398 | Antagonist activity against human galectin 9 N-terminal domain by fluorescence polarization assay | 2014 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
| Synthesis and evaluation of iminocoumaryl and coumaryl derivatized glycosides as galectin antagonists. |
| AID73819 | The compound was evaluated for the inhibition of glycogen phosphorylase | 1999 | Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
| Prediction of ligand-receptor binding thermodynamics by free energy force field three-dimensional quantitative structure-activity relationship analysis: applications to a set of glucose analogue inhibitors of glycogen phosphorylase. |
| AID1809544 | Binding affinity to recombinant Pseudomonas aeruginosa LecA expressed in Escherichia coli assessed as change in enthalpy by isothermal titration calorimetry | 2021 | Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
| Pillar[5]arene-Based Polycationic Glyco[2]rotaxanes Designed as |
| AID343833 | Binding affinity to human galectin2 by fluorescence polarization assay | 2008 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
| Protein subtype-targeting through ligand epimerization: talose-selectivity of galectin-4 and galectin-8. |
| AID1766483 | Binding affinity to human galectin-1 assessed as dissociation constant by competitive fluorescence polarization assay | 2021 | ACS medicinal chemistry letters, Nov-11, Volume: 12, Issue:11
| Structure-Guided Design of d-Galactal Derivatives with High Affinity and Selectivity for the Galectin-8 N-Terminal Domain. |
| AID1809546 | Binding affinity to recombinant Pseudomonas aeruginosa LecA expressed in Escherichia coli assessed as change in entropy by isothermal titration calorimetry | 2021 | Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
| Pillar[5]arene-Based Polycationic Glyco[2]rotaxanes Designed as |
| AID1766484 | Binding affinity to human galectin-2 assessed as dissociation constant by competitive fluorescence polarization assay | 2021 | ACS medicinal chemistry letters, Nov-11, Volume: 12, Issue:11
| Structure-Guided Design of d-Galactal Derivatives with High Affinity and Selectivity for the Galectin-8 N-Terminal Domain. |
| AID1766493 | Selectivity for human galectin-8N over human galectin-3 | 2021 | ACS medicinal chemistry letters, Nov-11, Volume: 12, Issue:11
| Structure-Guided Design of d-Galactal Derivatives with High Affinity and Selectivity for the Galectin-8 N-Terminal Domain. |
| AID1171662 | Induction of bacterial aggregation in Pseudomonas aeruginosa PAO1 assessed as number of aggregates per 100 uL of PBS cell solution at 100 uM by optical microscopy | 2014 | Journal of medicinal chemistry, Dec-26, Volume: 57, Issue:24
| Antiadhesive properties of glycoclusters against Pseudomonas aeruginosa lung infection. |
| AID1766487 | Binding affinity to human galectin-4 C terminal domain assessed as dissociation constant by competitive fluorescence polarization assay | 2021 | ACS medicinal chemistry letters, Nov-11, Volume: 12, Issue:11
| Structure-Guided Design of d-Galactal Derivatives with High Affinity and Selectivity for the Galectin-8 N-Terminal Domain. |
| AID1809540 | Binding affinity to recombinant Pseudomonas aeruginosa LecA expressed in Escherichia coli assessed as dissociation constant by isothermal titration calorimetry | 2021 | Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
| Pillar[5]arene-Based Polycationic Glyco[2]rotaxanes Designed as |
| AID1884996 | Binding affinity to Pseudomonas aeruginosa LecA assessed as dissociation constant | 2022 | Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13
| Small Carbohydrate Derivatives as Potent Antibiofilm Agents. |
| AID1171677 | Antimicrobial activity Pseudomonas aeruginosa PAO1 infected C57BL6/J mouse lung injury model assessed as effect on alveolar-capillary permeability using 5 mM compound pre-treated bacteria for infection | 2014 | Journal of medicinal chemistry, Dec-26, Volume: 57, Issue:24
| Antiadhesive properties of glycoclusters against Pseudomonas aeruginosa lung infection. |
| AID1171657 | Induction of bacterial aggregation in Pseudomonas aeruginosa PAO1 expressing deltalecA mutant at 6 to 5000 uM by optical microscopy | 2014 | Journal of medicinal chemistry, Dec-26, Volume: 57, Issue:24
| Antiadhesive properties of glycoclusters against Pseudomonas aeruginosa lung infection. |
| AID1766492 | Binding affinity to human galectin-9 C terminal domain assessed as dissociation constant by competitive fluorescence polarization assay | 2021 | ACS medicinal chemistry letters, Nov-11, Volume: 12, Issue:11
| Structure-Guided Design of d-Galactal Derivatives with High Affinity and Selectivity for the Galectin-8 N-Terminal Domain. |
| AID1373943 | Inhibition of Escherichia coli Heptosyltransferase I assessed as reduction in ADP release at 1 mM using ODLA and ADP-heptose substrates in presence of phospho(enol)pyruvate and NADH by pyruvate kinase and LDH based ADP/NADH coupling assay | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
| Synthesis, kinetics and inhibition of Escherichia coli Heptosyltransferase I by monosaccharide analogues of Lipid A. |
| AID1766511 | Selectivity for human galectin-8N over human galectin-4 C terminal domain | 2021 | ACS medicinal chemistry letters, Nov-11, Volume: 12, Issue:11
| Structure-Guided Design of d-Galactal Derivatives with High Affinity and Selectivity for the Galectin-8 N-Terminal Domain. |
| AID1171663 | Induction of bacterial aggregation in Pseudomonas aeruginosa PAO1 expressing deltalecA mutant assessed as number of aggregates per 100 uL of PBS cell solution at 100 uM by optical microscopy | 2014 | Journal of medicinal chemistry, Dec-26, Volume: 57, Issue:24
| Antiadhesive properties of glycoclusters against Pseudomonas aeruginosa lung infection. |
| AID1171655 | Binding affinity to Pseudomonas aeruginosa LecA by ITC method | 2014 | Journal of medicinal chemistry, Dec-26, Volume: 57, Issue:24
| Antiadhesive properties of glycoclusters against Pseudomonas aeruginosa lung infection. |
| AID1181396 | Antagonist activity against human galectin 7 by fluorescence polarization assay | 2014 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
| Synthesis and evaluation of iminocoumaryl and coumaryl derivatized glycosides as galectin antagonists. |
| AID1772855 | Binding affinity to human galactin-8 N terminal domain assessed as dissociation constant by competitive fluorescence polarization assay | 2021 | European journal of medicinal chemistry, Nov-05, Volume: 223 | Benzimidazole-galactosides bind selectively to the Galectin-8 N-Terminal domain: Structure-based design and optimisation. |
| AID343834 | Binding affinity to human galectin3 by fluorescence polarization assay | 2008 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
| Protein subtype-targeting through ligand epimerization: talose-selectivity of galectin-4 and galectin-8. |
| AID1541789 | Binding affinity at recombinant human N-terminal Galectin 4 expressed in Escherichia coli BL21 incubated for 5 mins by fluorescence anisotropy assay | | | |
| AID1766494 | Selectivity for human galectin-8N over human galectin-2 | 2021 | ACS medicinal chemistry letters, Nov-11, Volume: 12, Issue:11
| Structure-Guided Design of d-Galactal Derivatives with High Affinity and Selectivity for the Galectin-8 N-Terminal Domain. |
| AID1766488 | Binding affinity to human galectin-7 assessed as dissociation constant by competitive fluorescence polarization assay | 2021 | ACS medicinal chemistry letters, Nov-11, Volume: 12, Issue:11
| Structure-Guided Design of d-Galactal Derivatives with High Affinity and Selectivity for the Galectin-8 N-Terminal Domain. |
| AID513982 | Binding affinity to human galectin 7 at 4 degC by competitive fluorescence polarization assay | 2010 | Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
| 1H-1,2,3-triazol-1-yl thiodigalactoside derivatives as high affinity galectin-3 inhibitors. |
| AID1541792 | Binding affinity at recombinant human N-terminal Galectin 8 expressed in Escherichia coli BL21 incubated for 5 mins by fluorescence anisotropy assay | | | |
| AID362216 | Binding affinity to galectin 3 | 2008 | Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
| Synthesis of stable and selective inhibitors of human galectins-1 and -3. |
| AID1766513 | Selectivity for human galectin-8N over human galectin-9 N terminal domain | 2021 | ACS medicinal chemistry letters, Nov-11, Volume: 12, Issue:11
| Structure-Guided Design of d-Galactal Derivatives with High Affinity and Selectivity for the Galectin-8 N-Terminal Domain. |
| AID1541793 | Binding affinity at recombinant human C-terminal Galectin 8 expressed in Escherichia coli BL21 incubated for 5 mins by fluorescence anisotropy assay | | | |
| AID513981 | Binding affinity to human galectin 3 at 20 degC by competitive fluorescence polarization assay | 2010 | Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
| 1H-1,2,3-triazol-1-yl thiodigalactoside derivatives as high affinity galectin-3 inhibitors. |
| AID1576030 | Displacement of (3,3'-dideoxy-3-[4-(fluorescein-5-yl-carbonylaminomethyl)-1H-1,2,3-triazol-1-yl]-3'-(3,5-di-methoxybenzamido)-1,1'-sulfanediyl-di-beta-D-galactopyranoside) fluorescent probe from human galectin-1 by competitive fluorescence polarization as | 2019 | MedChemComm, Jun-01, Volume: 10, Issue:6
| Aminopyrimidine-galactose hybrids are highly selective galectin-3 inhibitors. |
| AID1809542 | Binding affinity to recombinant Pseudomonas aeruginosa LecA expressed in Escherichia coli assessed as gibbs free energy change by isothermal titration calorimetry | 2021 | Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
| Pillar[5]arene-Based Polycationic Glyco[2]rotaxanes Designed as |
| AID1766510 | Selectivity for human galectin-8N over human galectin-4 N terminal domain | 2021 | ACS medicinal chemistry letters, Nov-11, Volume: 12, Issue:11
| Structure-Guided Design of d-Galactal Derivatives with High Affinity and Selectivity for the Galectin-8 N-Terminal Domain. |
| AID1541794 | Binding affinity at recombinant human N-terminal Galectin 9 expressed in Escherichia coli BL21 incubated for 5 mins by fluorescence anisotropy assay | | | |
| AID1541790 | Binding affinity at recombinant human C-terminal Galectin 4 expressed in Escherichia coli BL21 incubated for 5 mins by fluorescence anisotropy assay | | | |
| AID343836 | Binding affinity to human galectin4C by fluorescence polarization assay | 2008 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
| Protein subtype-targeting through ligand epimerization: talose-selectivity of galectin-4 and galectin-8. |
| AID513984 | Binding affinity to human galectin 9 N-terminal domain at 20 degC by competitive fluorescence polarization assay | 2010 | Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
| 1H-1,2,3-triazol-1-yl thiodigalactoside derivatives as high affinity galectin-3 inhibitors. |
| AID73825 | Tested for inhibition constant against glycogen phosphorylase b | 1994 | Journal of medicinal chemistry, Aug-05, Volume: 37, Issue:16
| Comparative molecular field analysis using GRID force-field and GOLPE variable selection methods in a study of inhibitors of glycogen phosphorylase b. |
| AID1171664 | Induction of bacterial aggregation in Pseudomonas aeruginosa PAO1 expressing deltalecB mutant assessed as number of aggregates per 100 uL of PBS cell solution at 100 uM by optical microscopy | 2014 | Journal of medicinal chemistry, Dec-26, Volume: 57, Issue:24
| Antiadhesive properties of glycoclusters against Pseudomonas aeruginosa lung infection. |
| AID343837 | Binding affinity to human galectin8N by fluorescence polarization assay | 2008 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
| Protein subtype-targeting through ligand epimerization: talose-selectivity of galectin-4 and galectin-8. |
| AID1171671 | Inhibition of biofilm formation of Pseudomonas aeruginosa PAO1 at 0.1 to 5 mM after 24 hrs by crystal violet staining | 2014 | Journal of medicinal chemistry, Dec-26, Volume: 57, Issue:24
| Antiadhesive properties of glycoclusters against Pseudomonas aeruginosa lung infection. |
| AID977611 | Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB | 2008 | Proteins, Oct, Volume: 73, Issue:1
| Structure determination of Discoidin II from Dictyostelium discoideum and carbohydrate binding properties of the lectin domain. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |